Lynx1 Capital Management as of Sept. 30, 2023
Portfolio Holdings for Lynx1 Capital Management
Lynx1 Capital Management holds 18 positions in its portfolio as reported in the September 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Cabaletta Bio (CABA) | 21.2 | $32M | 2.1M | 15.22 | |
| Alpine Immune Sciences (ALPN) | 18.2 | $28M | 2.4M | 11.45 | |
| Merus N V (MRUS) | 17.9 | $27M | 1.2M | 23.58 | |
| Cymabay Therapeutics | 9.8 | $15M | 994k | 14.91 | |
| Tscan Therapeutics (TCRX) | 8.8 | $13M | 5.2M | 2.56 | |
| Gh Research Ordinary Shares (GHRS) | 7.3 | $11M | 1.1M | 10.05 | |
| Stoke Therapeutics (STOK) | 4.5 | $6.7M | 1.7M | 3.94 | |
| Autolus Therapeutics Spon Ads (AUTL) | 2.1 | $3.2M | 1.4M | 2.33 | |
| Pieris Pharmaceuticals (PIRS) | 1.9 | $2.9M | 9.8M | 0.30 | |
| Kinnate Biopharma (KNTE) | 1.8 | $2.8M | 2.0M | 1.40 | |
| Silence Therapeutics Ads (SLN) | 1.5 | $2.3M | 236k | 9.82 | |
| Bionomics Ads (BNOX) | 1.5 | $2.2M | 816k | 2.70 | |
| C4 Therapeutics Com Stk (CCCC) | 1.3 | $1.9M | 1.0M | 1.86 | |
| Theseus Pharmaceuticals | 1.2 | $1.9M | 702k | 2.69 | |
| Nektar Therapeutics (NKTR) | 0.7 | $1.1M | 1.8M | 0.60 | |
| Passage Bio (PASG) | 0.1 | $125k | 190k | 0.66 | |
| Zura Bio Class A Ord Shs (ZURA) | 0.0 | $66k | 9.9k | 6.60 | |
| Dbv Technologies S A Sponsored Adr (DBVT) | 0.0 | $25k | 18k | 1.36 |
